Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Condition Directory

Acute Lymphoblastic Leukemia clinical trials

Directory of U.S. ClinicalTrials.gov public records for Acute Lymphoblastic Leukemia. Browse Acute Lymphoblastic Leukemia recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 30, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 30, 2026, 2:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1863
Shown on this page
12
Current sort
Recently updated
Condition scope
Acute Lymphoblastic Leukemia
Additional filters apply within this condition.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

How Acute Lymphoblastic Leukemia studies are organized in the registry

ALL records split sharply between pediatric and adult populations, so the age filter changes the result set more than for most conditions. Lineage labels (B-cell, T-cell) and immunotherapy platforms such as CAR-T appear in titles and meaningfully narrow the portfolio.

Terms that often appear in related listings
B-cell ALL T-cell ALL pediatric ALL CAR-T

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Filter and sort this condition

These controls apply only within Acute Lymphoblastic Leukemia. Default order is Recently updated. Add location, sponsor, treatment, or recruitment status to narrow this condition page further.

Reset condition filters
Clear filters
Showing 337–348 of 1,863 matching trials for Acute Lymphoblastic Leukemia.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Recruiting Phase 3 Interventional

A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)

NCT06051409
View directory record Official record
Conditions
Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Interventions
Olverembatinib, Investigator's choice of TKI
Drug
Lead sponsor
Ascentage Pharma Group Inc.
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
16
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 30, 2026, 2:07 AM EDT
Recruiting No phase listed Observational

CAR T-cell Long-Term Follow-Up, Quality of Life and Adverse Reactions

NCT07048535
View directory record Official record
Conditions
B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 30, 2026, 2:07 AM EDT
Completed Phase 1 Interventional

Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies

NCT02315612
View directory record Official record
Conditions
NHL, Large Cell Lymphoma, Follicular Lymphoma, ALL, B-All, B-precursor ALL, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, B-Non Hodgkin Lymphoma, B-NHL
Interventions
CD22-CAR
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
3 Years to 39 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 30, 2026, 2:07 AM EDT
Recruiting Early Phase 1 Interventional

Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia

NCT06735690
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Anti-CD19-CAR CMV-specific T-lymphocytes, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Echocardiography, Leukapheresis, Lumbar Puncture, Magnetic Resonance Imaging, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine, Multigated Acquisition Scan, Positron Emission Tomography, Transplant Conditioning, X-Ray Imaging
Procedure · Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 30, 2026, 2:07 AM EDT
Terminated Phase 2 Interventional

A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia

NCT05268003
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Leukemia
Interventions
Ponatinib, Venetoclax, Mini-hyper CVD
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 30, 2026, 2:07 AM EDT
Recruiting Not applicable Interventional

Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication Adherence: Study 3

NCT06074666
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Pediatric
Interventions
CareMeds Intervention, Usual Care Group
Behavioral
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
3 Years to 9 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 30, 2026, 2:07 AM EDT
Recruiting Phase 1 Interventional

Pilot Imaging Study of Leukemia

NCT03633955
View directory record Official record
Conditions
Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Ambiguous Lineage Leukemia or Lymphoma, Myeloma
Interventions
FLT
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
4 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 30, 2026, 2:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Positive Youth Development in the Metaverse

NCT05858593
View directory record Official record
Conditions
Healthy, Healthy Lifestyle, Childhood ALL, Behavior, Child
Interventions
Virtual reality curriculum, No Virtual reality curriculum
Behavioral
Lead sponsor
University of Georgia
Other
Eligibility
9 Years to 17 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Athens, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 30, 2026, 2:07 AM EDT
Active, not recruiting Phase 1 Interventional

NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers

NCT05020678
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Mantle Cell Lymphoma, Indolent Lymphoma, Waldenstrom Macroglobulinemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Aggressive Lymphoma, Large-cell Lymphoma
Interventions
NKX019
Biological
Lead sponsor
Nkarta, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2038
U.S. locations
2
States / cities
Denver, Colorado • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 30, 2026, 2:07 AM EDT
Completed Phase 1 Interventional

Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic Leukemia

NCT04996160
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Pediatric, Relapsed Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
Interventions
Palbociclib, Dexamethasone, Bortezomib, Doxorubicin
Drug
Lead sponsor
Tanja Andrea Gruber
Other
Eligibility
Up to 25 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 30, 2026, 2:07 AM EDT
Recruiting Phase 1Phase 2 Interventional

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

NCT04329728
View directory record Official record
Conditions
Lymphoid Malignancies
Interventions
AVM0703
Drug
Lead sponsor
AVM Biotechnology Inc
Industry
Eligibility
12 Years to 95 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
11
States / cities
Duarte, California • Los Angeles, California • Whittier, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 30, 2026, 2:07 AM EDT
Terminated Phase 2 Interventional Results available

Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation

NCT03856216
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Lymphocytic Neoplasm, Lymphoma
Interventions
Allogeneic Bone Marrow Transplantation, Bendamustine, Filgrastim-sndz, Fludarabine, Inotuzumab Ozogamicin, Melphalan, Peripheral Blood Stem Cell Transplantation, Rituximab, Tacrolimus
Procedure · Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 30, 2026, 2:07 AM EDT

About this Acute Lymphoblastic Leukemia clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Acute Lymphoblastic Leukemia as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Acute Lymphoblastic Leukemia.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Acute Lymphoblastic Leukemia.